دورية أكاديمية
Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
| العنوان: | Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas. |
|---|---|
| المؤلفون: | Han LM; Department of Pathology, University of California San Francisco, San Francisco, California., Lee KW; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California., Uludag G; Department of Pathology, University of California San Francisco, San Francisco, California., Seider MI; Department of Ophthalmology, Kaiser Permanente San Francisco, San Francisco, California., Afshar AR; Ocular Oncology Service, Department of Ophthalmology, Wayne & Gladys Valley Center for Vision, University of California San Francisco, San Francisco, California., Bloomer MM; Department of Pathology, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California., Pekmezci M; Department of Pathology, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; San Francisco Veterans Affairs Medical Center, San Francisco, California. Electronic address: melike.pekmezci@ucsf.edu. |
| المصدر: | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2023 Apr; Vol. 36 (4), pp. 100081. Date of Electronic Publication: 2023 Jan 10. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 8806605 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-0285 (Electronic) Linking ISSN: 08933952 NLM ISO Abbreviation: Mod Pathol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : [New York] : Elsevier Inc. Original Publication: Baltimore, MD : Williams & Wilkins, c1988- |
| مواضيع طبية MeSH: | Melanoma*/pathology , Uveal Neoplasms*/metabolism, Adult ; Humans ; Prognosis ; Immunohistochemistry ; Retrospective Studies ; Tumor Suppressor Proteins/genetics ; Ubiquitin Thiolesterase/genetics ; Antigens, Neoplasm |
| مستخلص: | Uveal melanoma (UM) is the most common primary intraocular tumor in adults, and despite excellent local control, more than 50% of patients develop and die from metastatic disease. Loss of BAP1 nuclear staining, a surrogate marker of BAP1 mutation, and preferentially expressed antigen in melanoma (PRAME) messenger RNA overexpression, as assessed using qPCR, have previously been shown to correlate with increased metastasis rate in UM. In this study, we demonstrated that UM could be successfully risk-stratified using a combination of BAP1 and PRAME immunohistochemical (IHC) stains. We retrospectively reviewed 318 UM cases with sufficient tissue and performed BAP1 and PRAME IHC to stratify them as BAP1+/PRAME- (group 1, n = 135), BAP1+/PRAME+ (group 2, n = 43), BAP1-/PRAME- (group 3, n = 94), and BAP1-/PRAME+ (group 4, n = 46). Increasing the study risk group on the basis of loss of BAP1 expression and positive PRAME staining was associated with a higher rate of metastasis and disease-specific death and lower metastasis-free survival (MFS) and disease-specific survival (DSS). Among tumors with loss of BAP1 staining, PRAME positivity was associated with shorter MFS (P = .018) and showed a trend toward shorter DSS (P = .061). Among tumors with retained BAP1 staining, PRAME positivity was associated with shorter MFS and DSS (P = .001 and P = .021, respectively). In summary, a combination of BAP1 and PRAME IHC can be used for risk stratification of UMs. (Published by Elsevier Inc.) |
| معلومات مُعتمدة: | K23 EY027466 United States EY NEI NIH HHS |
| فهرسة مساهمة: | Keywords: BAP1; IHC; PRAME; immunohistochemistry; uveal melanoma |
| المشرفين على المادة: | 0 (Tumor Suppressor Proteins) EC 3.4.19.12 (Ubiquitin Thiolesterase) 0 (BAP1 protein, human) 0 (PRAME protein, human) 0 (Antigens, Neoplasm) |
| SCR Disease Name: | Uveal melanoma |
| تواريخ الأحداث: | Date Created: 20230214 Date Completed: 20230425 Latest Revision: 20231024 |
| رمز التحديث: | 20231024 |
| DOI: | 10.1016/j.modpat.2022.100081 |
| PMID: | 36788079 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1530-0285 |
|---|---|
| DOI: | 10.1016/j.modpat.2022.100081 |